
Sign up to save your podcasts
Or
In his weekly clinical update, Dr. Griffin discusses the public health significance of finding autochthonous melioidosis cases in the continental United States, human neural larva migrans caused by Ophidascaris robertsi ascarid, Project nextgen awards over $1.4 billion to develop the future of COVID-19 vaccines and therapeutics, excess all-cause mortality in China after ending the zero COVID policy, international pediatric COVID-19 severity over the course of the pandemic, differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination, Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical outcomes associated with overestimation of oxygen saturation by pulse oximetry in patients hospitalized with COVID-19, risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination.
Click arrow to play Download TWiV 1040 (19 MB .mp3, 27 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
4.7
205205 ratings
In his weekly clinical update, Dr. Griffin discusses the public health significance of finding autochthonous melioidosis cases in the continental United States, human neural larva migrans caused by Ophidascaris robertsi ascarid, Project nextgen awards over $1.4 billion to develop the future of COVID-19 vaccines and therapeutics, excess all-cause mortality in China after ending the zero COVID policy, international pediatric COVID-19 severity over the course of the pandemic, differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination, Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical outcomes associated with overestimation of oxygen saturation by pulse oximetry in patients hospitalized with COVID-19, risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination.
Click arrow to play Download TWiV 1040 (19 MB .mp3, 27 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
6,335 Listeners
2,057 Listeners
455 Listeners
517 Listeners
12,140 Listeners
168 Listeners
291 Listeners
1,369 Listeners
16,909 Listeners
269 Listeners
3,470 Listeners
619 Listeners
2,041 Listeners
85 Listeners
49 Listeners